THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN), provided investors with an update on the company’s late-stage and early-stage pipeline during the previously webcast UBS Global Life Sciences Conference in New York on Sept. 27, 2007. Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development, represented Amgen for the first time at a major investor conference this year; his presentation coincided with the publication of key Amgen studies presented at medical conferences in Europe and the United States.
